ストックスクリーナーアプリを入手
1.01
17.73%
0.1521
前日終値:
$0.8579
開ける：
$0.88
24時間の取引高:
970.51K
Relative Volume:
1.14
時価総額：
$32.38M
収益：
-
当期純損益:
$-42.37M
株価収益率:
-0.9452
EPS:
-1.0686
ネットキャッシュフロー:
$-34.94M
1週間 パフォーマンス:
+38.93%
1か月 パフォーマンス:
-15.83%
6か月 パフォーマンス:
-78.09%
1年 パフォーマンス:
-65.99%
1日の値動き範囲:
$0.8701
$1.07
1週間の範囲:
$0.6844
$1.07
52週間の値動き範囲:
$0.6844
$5.75
Skye Bioscience Inc Stock (SKYE) Company Profile
名前
Skye Bioscience Inc
セクター
電話
(858) 410-0266
住所
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
SKYE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.83 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.82 | 418.21M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
7.30 | 329.86M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
48.05 | 0 | 0 | 0 | 0 | 0.00 |
|
QQQE
Direxion NASDAQ-100 Equal Weigh
|
105.25 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-06 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-06 | ダウングレード | Craig Hallum | Buy → Hold |
| 2025-08-15 | 開始されました | Evercore ISI | Outperform |
| 2025-02-28 | 開始されました | William Blair | Outperform |
| 2024-09-30 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-09 | 開始されました | Craig Hallum | Buy |
| 2024-05-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-04-12 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Skye Bioscience Inc (SKYE) 最新ニュース
Levi & Korsinsky Notifies Skye Bioscience, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – SKYE - GlobeNewswire
ROSEN, A TOP-RANKED LAW FIRM, Encourages Skye Bioscience, - GlobeNewswire
SKYE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
SKYE LAWSUIT ALERT: Levi & Korsinsky Notifies Skye Bioscience, Inc. InvestorsLead Plaintiff Deadline January 16, 2026 - ACCESS Newswire
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm - PR Newswire
Lost Money on Skye Bioscience, Inc. (SKYE)? Contact Levi & Korsinsky Before January 16, 2026 to Join Class Action - ACCESS Newswire
HALO, Skye Bioscience team up on obesity drug development - Longevity.Technology
Skye Bioscience, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your RightsSKYE - Finviz
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors - GlobeNewswire
Fibonacci Retracement Aligns with Support in Rudra Ecovation LimitedEx-Dividend Date Alerts & Free Long-Term Investment Planning - earlytimes.in
Shareholders of Skye Bioscience, Inc. (SKYE): Protect Your Rights Before January 16, 2026Contact Levi & Korsinsky - ACCESS Newswire
Shareholders SueWallSt in New Class Action Against Skye Bioscience, Inc.Act Now (2026-01-05) - Seeking Alpha
Citizens reiterates Market Outperform rating on Skye Bioscience stock By Investing.com - Investing.com Canada
The Gross Law Firm Notifies Shareholders of Skye Bioscience, Inc - GuruFocus
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Halozyme Therapeutics, Skye Bioscience Collaborate to Evaluate Nimacimab for Obesity Treatment - marketscreener.com
Skye Bioscience Licenses Halozyme’s ENHANZE Drug Delivery Technology - Contract Pharma
The Gross Law Firm Notifies Shareholders of Skye Bioscience, Inc.(SKYE) of a Class Action Lawsuit and an Upcoming Deadline - Barchart.com
Skye Bioscience stock jumps after Halozyme collaboration for obesity drug By Investing.com - Investing.com Nigeria
Halozyme Therapeutics (HALO) Partners with Skye Bioscience for I - GuruFocus
Halozyme (HALO) Partners with Skye Bioscience for Obesity Treatm - GuruFocus
Skye Bioscience rises as it partners with Halozyme on obesity drug - TradingView — Track All Markets
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity - The Manila Times
SKYE ALERT: Securities Fraud Class Action Launched Against Skye Bioscience, Inc.January 16, 2026 Deadline - ACCESS Newswire
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Skye Bioscience, Inc. (SKYE) Investors of January 16, 2026 Deadline - ACCESS Newswire
Levi & Korsinsky Urges Skye Bioscience, Inc. (SKYE) Shareholders to Act Before Lead Plaintiff Deadline January 16, 2026 - ACCESS Newswire
Class Action Lawsuit Filed: Skye Bioscience, Inc. (SKYE) – Join by January 16, 2026 – Contact Levi & Korsinsky - ACCESS Newswire
Will Breakout in Rathi Bars Limited Sustain Through Next WeekPortfolio Allocation Tips & Double Or Triple Returns - earlytimes.in
Securities Fraud Class Action Filed Against Skye Bioscience, Inc. (SKYE)Levi & Korsinsky Reminds Investors of January 16, 2026 - ACCESS Newswire
Lost Money on Skye Bioscience, Inc.(SKYE)? Join Class Action Sui - GuruFocus
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - FinancialContent
Skye Bioscience, Inc. (SKYE) LawsuitInvestors Urged to Contact Levi & Korsinsky Before January 16, 2026 - ACCESS Newswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, A TOP RANKED LAW FIRM, Encourages Skye Bioscience, - GlobeNewswire
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - The Malaysian Reserve
Class Action Alert: Levi & Korsinsky Reminds Skye Bioscience, Inc. (SKYE) Investors of January 16, 2026 Deadline - ACCESS Newswire
Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit - GlobeNewswire
Skye Bioscience stock jumps after Halozyme collaboration for obesity drug - Investing.com
Securities Fraud Class Action Filed Against Skye Bioscience, Inc. (SKYE) – Levi & Korsinsky Reminds Investors of January 16, 2026 - ACCESS Newswire
Skye Bioscience, Inc. (SKYE) Lawsuit – Investors Urged to Contact Levi & Korsinsky Before January 16, 2026 - ACCESS Newswire
January 16, 2026 Deadline: Join Class Action Lawsuit Against Skye Bioscience, Inc. (SKYE)Contact Levi & Korsinsky - ACCESS Newswire
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit - PR Newswire
Shareholders that lost money on Skye Bioscience, Inc.(SKYE) should contact Levi & Korsinsky about pending Class ActionSKYE - Sahm
Class Action Lawsuit Filed: Skye Bioscience, Inc. (SKYE)Join by January 16, 2026Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Notifies Skye Bioscience, Inc. (SKYE) Shareholders of Class Action Lawsuit and January 16, 2026 Deadline - ACCESS Newswire
Levi & Korsinsky Reminds Skye Bioscience, Inc. Investors of - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Skye Bioscience, - GlobeNewswire
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
SKYE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Skye Bioscience, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Skye Bioscience Inc (SKYE) 財務データ
収益
当期純利益
現金流量
EPS
2.52%
0.07%
大文字化:
|
ボリューム (24 時間):